Sciomics

Executive Summary

Sciomics is a German biotechnology company founded in 2013 that specializes in precision medicine through high-content proteomics services. The company leverages its proprietary antibody microarray platform to analyze over 1,400 proteins and their post-translational modifications, enabling biomarker discovery, drug development, and disease mechanism studies. By providing cutting-edge protein profiling services to researchers and pharmaceutical partners, Sciomics aims to accelerate the translation of proteomic insights into clinical applications. The company operates primarily in the pre-clinical stage and is privately held, with its headquarters in Heidelberg, Germany. As a service-oriented proteomics provider, Sciomics is well positioned to capitalize on the growing demand for multi-omics integration in drug development. Its platform offers a differentiated approach by enabling high-throughput, multiplexed protein analysis without the need for costly mass spectrometry equipment. While the company has not disclosed financials or major partnerships, its focus on antibody-based microarrays places it in a competitive niche within the proteomics market, particularly for applications requiring sensitive detection of low-abundance proteins and modifications. The continued expansion of precision medicine and biomarker-driven trials presents a favorable tailwind for Sciomics' growth.

Upcoming Catalysts (preview)

• Q4 2026Announcement of a strategic partnership with a major pharmaceutical company40% success
• Q2 2027Launch of an expanded protein panel covering >2,000 targets50% success
• Q3 2026Securing Series A funding to scale commercial operations30% success